Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Jason Lu, Ph.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
Cornell University, USAPhD12/2018Biological Engineering
Cornell University, USAMS05/2017Biological Engineering
Cornell University, USAM.Eng05/2013Biomedical Engineering
National Taiwan University, TaiwanBS01/2010Chemical Engineering
National Taiwan University, TaiwanBS01/2010Civil Engineering

Overview

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lin CH, Yap YS, Lee KH, Im SA, Naito Y, Yeo W, Ueno T, Kwong A, Li H, Huang SM, Leung R, Han W, Tan B, Hu FC, Huang CS, Cheng AL, Lu YS. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. J Natl Cancer Inst. 2019 12 01; 111(12):1298-1306. PMID: 31093668.
    Citations: 10     Fields:    Translation:Humans
  2. Chen CH, Lu YS, Cheng AL, Huang CS, Kuo WH, Wang MY, Chao M, Chen IC, Kuo CW, Lu TP, Lin CH. Disparity in Tumor Immune Microenvironment of Breast Cancer and Prognostic Impact: Asian Versus Western Populations. Oncologist. 2020 01; 25(1):e16-e23. PMID: 31371522.
    Citations: 10     Fields:    Translation:Humans
  3. Yeo W, Ueno T, Lin CH, Liu Q, Lee KH, Leung R, Naito Y, Park YH, Im SA, Li H, Yap YS, Lu YS. Treating HR+/HER2- breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Res Treat. 2019 Oct; 177(3):549-559. PMID: 31270763.
    Citations: 7     Fields:    Translation:Humans
  4. Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med. 2019 07 25; 381(4):307-316. PMID: 31166679.
    Citations: 106     Fields:    Translation:HumansCTClinical Trials
  5. Iwata H, Masuda N, Kim SB, Inoue K, Rai Y, Fujita T, Chiu J, Ohtani S, Takahashi M, Miyaki T, Lu YS, Xu B, Yap YS, Bustam A, Yao B, Zhang B, Bryce R, Chan A. Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. Future Oncol. 2019 Jul; 15(21):2489-2501. PMID: 31140297.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  6. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, Pápai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019 05 16; 380(20):1929-1940. PMID: 31091374.
    Citations: 260     Fields:    Translation:HumansCTClinical Trials
  7. Yang MH, Chen IC, Lu YS. PI3K inhibitor provides durable response in metastatic metaplastic carcinoma of the breast: A hidden gem in the BELLE-4 study. J Formos Med Assoc. 2019 Sep; 118(9):1333-1338. PMID: 30577988.
    Citations: 6     Fields:    Translation:Humans
  8. Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 07; 19(7):904-915. PMID: 29804902.
    Citations: 104     Fields:    Translation:HumansCTClinical Trials
  9. Lin CH, Chuang PY, You SL, Chiang CJ, Huang CS, Wang MY, Chao M, Lu YS, Cheng AL, Tang CH. Effect of glucocorticoid use on survival in patients with stage I-III breast cancer. Breast Cancer Res Treat. 2018 Aug; 171(1):225-234. PMID: 29761323.
    Citations: 2     Fields:    Translation:HumansPHPublic Health
  10. Chen TW, Yeh DC, Chao TY, Lin CH, Chow LW, Chang DY, Hsieh YY, Huang SM, Cheng AL, Lu YS, Consortium TBC. A Phase I/II study of the combination of lapatinib and oral vinorelbine in HER2-positive metastatic breast cancer. Jpn J Clin Oncol. 2018 Mar 01; 48(3):242-247. PMID: 29315394.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  11. Chiu HH, Liao HW, Shao YY, Lu YS, Lin CH, Tsai IL, Kuo CH. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Anal Chim Acta. 2018 Aug 17; 1019:93-102. PMID: 29625688.
    Citations: 4     Fields:    Translation:Humans
  12. An D, Chiu A, Flanders JA, Song W, Shou D, Lu YC, Grunnet LG, Winkel L, Ingvorsen C, Christophersen NS, Fels JJ, Sand FW, Ji Y, Qi L, Pardo Y, Luo D, Silberstein M, Fan J, Ma M. Designing a retrievable and scalable cell encapsulation device for potential treatment of type 1 diabetes. Proc Natl Acad Sci U S A. 2018 01 09; 115(2):E263-E272. PMID: 29279393.
    Citations: 21     Fields:    Translation:HumansAnimals
  13. Lu YC, Fu DJ, An D, Chiu A, Schwartz R, Nikitin AY, Ma M. Scalable Production and Cryostorage of Organoids Using Core-Shell Decoupled Hydrogel Capsules. Adv Biosyst. 2017 Dec; 1(12). PMID: 29607405.
    Citations: 6     
  14. Chiu HH, Tsai IL, Lu YS, Lin CH, Kuo CH. Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. Anal Bioanal Chem. 2017 Nov; 409(28):6583-6593. PMID: 28963670.
    Citations: 1     Fields:    Translation:Humans
  15. Chen IC, Hsiao LP, Huang IW, Yu HC, Yeh LC, Lin CH, Wei-Wu Chen T, Cheng AL, Lu YS. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. Sci Rep. 2017 08 29; 7(1):9842. PMID: 28852212.
    Citations: 10     Fields:    Translation:HumansCells
  16. Lai SF, Chen YH, Kuo WH, Lien HC, Wang MY, Lu YS, Lo C, Kuo SH, Cheng AL, Huang CS. Locoregional Recurrence Risk for Postmastectomy Breast Cancer Patients With T1-2 and One to Three Positive Lymph Nodes Receiving Modern Systemic Treatment Without Radiotherapy. Ann Surg Oncol. 2016 11; 23(12):3860-3869. PMID: 27436202.
    Citations: 11     Fields:    Translation:Humans
  17. Chen BB, Lu YS, Lin CH, Chen WW, Wu PF, Hsu CY, Yu CW, Wei SY, Cheng AL, Shih TT. A pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer. BMC Cancer. 2016 07 13; 16:466. PMID: 27412562.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  18. Song W, Tung CK, Lu YC, Pardo Y, Wu M, Das M, Kao DI, Chen S, Ma M. Dynamic self-organization of microwell-aggregated cellular mixtures. Soft Matter. 2016 Jun 29; 12(26):5739-46. PMID: 27275624.
    Citations: 9     Fields:    Translation:HumansCells
  19. Love RR, Hossain SM, Hussain MM, Mostafa MG, Laudico AV, Siguan SS, Adebamowo C, Sun JZ, Fei F, Shao ZM, Liu Y, Akram Hussain SM, Zhang B, Cheng L, Panigaro S, Walta F, Chuan JH, Mirasol-Lumague MR, Yip CH, Navarro NS, Huang CS, Lu YS, Ferdousy T, Salim R, Akhter C, Nahar S, Uy G, Young GS, Hade EM, Jarjoura D. Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer. Eur J Cancer. 2016 06; 60:107-16. PMID: 27107325.
    Citations: 2     Fields:    Translation:Humans
  20. Chen IC, Chang YC, Lu YS, Chung KP, Huang CS, Lu TP, Kuo WH, Wang MY, Kuo KT, Wu PF, Hsueh TH, Shen CY, Lin CH, Cheng AL. Clinical Relevance of Liver Kinase B1(LKB1) Protein and Gene Expression in Breast Cancer. Sci Rep. 2016 Feb 15; 6:21374. PMID: 26877155.
    Citations: 6     Fields:    Translation:Humans
  21. Lin CH, Chen IC, Huang CS, Hu FC, Kuo WH, Kuo KT, Wang CC, Wu PF, Chang DY, Wang MY, Chang CH, Chen WW, Lu YS, Cheng AL. TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. Sci Rep. 2015 Dec 16; 5:17879. PMID: 26671300.
    Citations: 2     Fields:    Translation:Humans
  22. Song W, Lu YC, Frankel AS, An D, Schwartz RE, Ma M. Engraftment of human induced pluripotent stem cell-derived hepatocytes in immunocompetent mice via 3D co-aggregation and encapsulation. Sci Rep. 2015 Nov 23; 5:16884. PMID: 26592180.
    Citations: 22     Fields:    Translation:HumansAnimalsCells
  23. Lin CH, Shen CY, Lee JH, Huang CS, Yang CH, Kuo WH, Chang DY, Hsiung CN, Kuo KT, Chen WW, Chen IC, Wu PF, Kuo SH, Chen CJ, Lu YS, Cheng AL. High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country. PLoS One. 2015; 10(4):e0124908. PMID: 25909194.
    Citations: 4     Fields:    Translation:Humans
  24. Wu PF, Lin CH, Kuo CH, Chen WW, Yeh DC, Liao HW, Huang SM, Cheng AL, Lu YS. A pilot study of bevacizumab combined with etoposide and cisplatin in breast cancer patients with leptomeningeal carcinomatosis. BMC Cancer. 2015 Apr 17; 15:299. PMID: 25928457.
    Citations: 21     Fields:    Translation:HumansAnimalsCTClinical Trials
  25. Chen IC, Lin CH, Jan IS, Cheng AL, Lu YS. Bevacizumab might potentiate the chemotherapeutic effect in breast cancer patients with leptomeningeal carcinomatosis. J Formos Med Assoc. 2016 Apr; 115(4):243-8. PMID: 25890495.
    Citations: 3     Fields:    Translation:Humans
  26. Wu LA, Chang RF, Huang CS, Lu YS, Chen HH, Chen JY, Chang YC. Evaluation of the treatment response to neoadjuvant chemotherapy in locally advanced breast cancer using combined magnetic resonance vascular maps and apparent diffusion coefficient. J Magn Reson Imaging. 2015 Nov; 42(5):1407-20. PMID: 25875904.
    Citations: 3     Fields:    Translation:Humans
  27. Bussche L, Harman RM, Syracuse BA, Plante EL, Lu YC, Curtis TM, Ma M, Van de Walle GR. Microencapsulated equine mesenchymal stromal cells promote cutaneous wound healing in vitro. Stem Cell Res Ther. 2015 Apr 11; 6:66. PMID: 25889766.
    Citations: 15     Fields:    Translation:AnimalsCells
  28. Lu YS, Chen TW, Lin CH, Yeh DC, Tseng LM, Wu PF, Rau KM, Chen BB, Chao TC, Huang SM, Huang CS, Shih TT, Cheng AL. Bevacizumab preconditioning followed by Etoposide and Cisplatin is highly effective in treating brain metastases of breast cancer progressing from whole-brain radiotherapy. Clin Cancer Res. 2015 Apr 15; 21(8):1851-8. PMID: 25700303.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  29. Yen-Chun Lu, Wei Song, Duo An, Beum Jun Kim, Robert Schwartz, Mingming Wu, Minglin Ma. Designing compartmentalized hydrogel microparticles for cell encapsulation and scalable 3D cell culture. Journal of Materials Chemistry B. 2014; 3(3):353-360. View Publication.
  30. An D, Ji Y, Chiu A, Lu YC, Song W, Zhai L, Qi L, Luo D, Ma M. Developing robust, hydrogel-based, nanofiber-enabled encapsulation devices (NEEDs) for cell therapies. Biomaterials. 2015 Jan; 37:40-8. PMID: 25453936.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  31. Chen TW, Chen HM, Lin CH, Huang CS, Cheng AL, Lai MS, Lu YS. No increased venous thromboembolism risk in Asian breast cancer patients receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2014 Nov; 148(1):135-42. PMID: 25240736.
    Citations: 4     Fields:    Translation:Humans
  32. Liao HW, Tsai IL, Chen GY, Lu YS, Lin CH, Kuo CH. Quantification of target analytes in various biofluids using a postcolumn infused-internal standard method combined with matrix normalization factors in liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr A. 2014 Sep 05; 1358:85-92. PMID: 25022483.
    Citations: 1     Fields:    Translation:Humans
  33. Song W, An D, Kao DI, Lu YC, Dai G, Chen S, Ma M. Nanofibrous microposts and microwells of controlled shapes and their hybridization with hydrogels for cell encapsulation. ACS Appl Mater Interfaces. 2014 May 28; 6(10):7038-44. PMID: 24806031.
    Citations: 1     Fields:    Translation:HumansCells
  34. Lin CH, Chuang PY, Chiang CJ, Lu YS, Cheng AL, Kuo WH, Huang CS, Lai MS, You SL, Tang CH. Distinct clinicopathological features and prognosis of emerging young-female breast cancer in an East Asian country: a nationwide cancer registry-based study. Oncologist. 2014 Jun; 19(6):583-91. PMID: 24807917.
    Citations: 11     Fields:    Translation:Humans
  35. Chen WW, Chang DY, Huang SM, Lin CH, Hsu C, Lin MH, Huang CS, Lu YS, Cheng AL. The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: a comparative study of the efficacy of anthracyclines and non-anthracyclines. Breast. 2013 Dec; 22(6):1148-54. PMID: 23968865.
    Citations: 1     Fields:    Translation:Humans
  36. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct; 115(1):61-70. PMID: 23817810.
    Citations: 4     Fields:    Translation:HumansCells
  37. Lin CH, Liu JM, Lu YS, Lan C, Lee WC, Kuo KT, Wang CC, Chang DY, Huang CS, Cheng AL. Clinical significance of ESR1 gene copy number changes in breast cancer as measured by fluorescence in situ hybridisation. J Clin Pathol. 2013 Feb; 66(2):140-5. PMID: 23268322.
    Citations: 4     Fields:    Translation:Humans
  38. Liang YH, Wu PF, Lin CH, Lu YS. Hashimoto's encephalopathy as the cause of deteriorating consciousness during treatment of leptomeningeal carcinomatosis from breast cancer. J Clin Oncol. 2012 Nov 20; 30(33):e358-9. PMID: 23045590.
    Citations:    Fields:    Translation:Humans
  39. Lu YS, Chou CH, Tzen KY, Gao M, Cheng AL, Kulp SK, Cheng JC. Radiosensitizing effect of a phenylbutyrate-derived histone deacetylase inhibitor in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2012 Jun 01; 83(2):e181-9. PMID: 22381897.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  40. Shao YY, Lin ZZ, Hsu C, Lee KD, Hsiao CH, Lu YS, Huang CC, Shen YC, Hsu CH, Cheng AL. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012; 82(1):59-66. PMID: 22310088.
    Citations: 12     Fields:    Translation:HumansCellsCTClinical Trials
  41. Lin CH, Chen YC, Chiang CJ, Lu YS, Kuo KT, Huang CS, Cheng WF, Lai MS, You SL, Cheng AL. The emerging epidemic of estrogen-related cancers in young women in a developing Asian country. Int J Cancer. 2012 Jun 01; 130(11):2629-37. PMID: 21702035.
    Citations: 17     Fields:    Translation:Humans
  42. Lin CH, Lu YS, Huang CS, Kuo KT, Wang CC, You SL, Lin PH, Chang DY, Kuo WH, Chang KJ, Cheng AL. Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients? J Clin Pathol. 2011 Sep; 64(9):781-7. PMID: 21642658.
    Citations: 4     Fields:    Translation:Humans
  43. Yeh PY, Lu YS, Ou DL, Cheng AL. I?B kinases increase Myc protein stability and enhance progression of breast cancer cells. Mol Cancer. 2011 May 16; 10:53. PMID: 21575199.
    Citations: 14     Fields:    Translation:HumansCells
  44. Wang J, Shih TT, Yen RF, Lu YS, Chen CY, Mao TL, Lin CH, Kuo WH, Tsai YS, Chang KJ, Chien KL. The association of infrared imaging findings of the breast with hormone receptor and human epidermal growth factor receptor 2 status of breast cancer. Acad Radiol. 2011 Feb; 18(2):212-9. PMID: 21126889.
    Citations: 2     Fields:    Translation:Humans
  45. Lu YS, Chen DR, Tseng LM, Yeh DC, Chen ST, Hsieh CM, Wang HC, Yeh HT, Kuo SH, Huang CS. Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer. Cancer Chemother Pharmacol. 2011 Jun; 67(6):1257-63. PMID: 20700740.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  46. Chiang CT, Yeh PY, Gao M, Chen CW, Yeh LC, Feng WC, Kuo SH, Hsu CH, Lu YS, Cheng AL. Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma. Cancer Lett. 2010 Dec 08; 298(2):195-203. PMID: 20673698.
    Citations: 9     Fields:    Translation:HumansCells
  47. Lin PH, Lu YS, Lin CH, Chang DY, Huang CS, Cheng AL, Yeh KH. Vinorelbine plus 24-hour infusion of high-dose 5-fluorouracil and leucovorin as effective palliative chemotherapy for breast cancer patients with acute disseminated intravascular coagulation. Anticancer Res. 2010 Jul; 30(7):3087-91. PMID: 20683060.
    Citations: 3     Fields:    Translation:Humans
  48. Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS, Moon H. Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib. Jpn J Clin Oncol. 2010 Nov; 40(11):999-1013. PMID: 20542996.
    Citations: 4     Fields:    Translation:Humans
  49. Shao YY, Kuo KT, Hu FC, Lu YS, Huang CS, Liau JY, Lee WC, Hsu C, Kuo WH, Chang KJ, Lin CH, Cheng AL. Predictive and prognostic values of tau and ERCC1 in advanced breast cancer patients treated with paclitaxel and cisplatin. Jpn J Clin Oncol. 2010 Apr; 40(4):286-93. PMID: 20085902.
    Citations: 12     Fields:    Translation:Humans
  50. Huang CS, Lin CH, Lu YS, Shen CY. Unique features of breast cancer in Asian women--breast cancer in Taiwan as an example. J Steroid Biochem Mol Biol. 2010 Feb 28; 118(4-5):300-3. PMID: 20045728.
    Citations: 20     Fields:    Translation:Humans
  51. Lin CH, Lien HC, Hu FC, Lu YS, Kuo SH, Wu LC, You SL, Cheng AL, Chang KJ, Huang CS. Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy. J Zhejiang Univ Sci B. 2010 Jan; 11(1):1-9. PMID: 20043345.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  52. Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS, Voravud N, Shao ZM, Pritchard KI. Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009 Nov; 10(11):1077-85. PMID: 19880061.
    Citations: 6     Fields:    Translation:Humans
  53. Ou DL, Shen YC, Liang JD, Liou JY, Yu SL, Fan HH, Wang DS, Lu YS, Hsu C, Cheng AL. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma. Clin Cancer Res. 2009 Sep 15; 15(18):5820-8. PMID: 19737956.
    Citations: 18     Fields:    Translation:HumansCells
  54. Wu PF, Kuo KT, Kuo LT, Lin YT, Lee WC, Lu YS, Yang CH, Wu RM, Tu YK, Tasi JC, Tseng HM, Tseng SH, Cheng AL, Lin CH. O(6)-Methylguanine-DNA methyltransferase expression and prognostic value in brain metastases of lung cancers. Lung Cancer. 2010 Jun; 68(3):484-90. PMID: 19740564.
    Citations: 15     Fields:    Translation:HumansCells
  55. Lin CH, Liau JY, Lu YS, Huang CS, Lee WC, Kuo KT, Shen YC, Kuo SH, Lan C, Liu JM, Kuo WH, Chang KJ, Cheng AL. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev. 2009 Jun; 18(6):1807-14. PMID: 19505913.
    Citations: 36     Fields:    Translation:Humans
  56. Chen KF, Yeh PY, Hsu C, Hsu CH, Lu YS, Hsieh HP, Chen PJ, Cheng AL. Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway. J Biol Chem. 2009 Apr 24; 284(17):11121-33. PMID: 19261616.
    Citations: 35     Fields:    Translation:HumansCells
  57. Wang SS, Liu KN, Lu YC. Amyloid fibrillation of hen egg-white lysozyme is inhibited by TCEP. Biochem Biophys Res Commun. 2009 Apr 17; 381(4):639-42. PMID: 19248768.
    Citations: 5     Fields:    Translation:AnimalsCells
  58. Gao M, Yeh PY, Lu YS, Chang WC, Kuo ML, Cheng AL. NF-kappaB p50 promotes tumor cell invasion through negative regulation of invasion suppressor gene CRMP-1 in human lung adenocarcinoma cells. Biochem Biophys Res Commun. 2008 Nov 14; 376(2):283-7. PMID: 18782567.
    Citations: 6     Fields:    Translation:HumansCells
  59. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2008 Aug 15; 68(16):6698-707. PMID: 18701494.
    Citations: 53     Fields:    Translation:HumansAnimalsCells
  60. Kuo SH, Lien HC, You SL, Lu YS, Lin CH, Chen TZ, Huang CS. Dose variation and regimen modification of adjuvant chemotherapy in daily practice affect survival of stage I-II and operable stage III Taiwanese breast cancer patients. Breast. 2008 Dec; 17(6):646-53. PMID: 18595699.
    Citations: 5     Fields:    Translation:Humans
  61. Shih IL, Lu YS, Wang HP, Liu KL. Pneumatosis coli after etoposide chemotherapy for breast cancer. J Clin Oncol. 2007 Apr 20; 25(12):1623-5. PMID: 17443004.
    Citations: 8     Fields:    Translation:Humans
  62. Lin CC, Cheng AL, Hsu CH, Lu YS, Hsu C, Yeh KH, Wu CY, Huang CS, Yang CH. A phase II trial of weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in patients with chemotherapy-pretreated metastatic breast cancer. Anticancer Res. 2007 Jan-Feb; 27(1B):641-5. PMID: 17348454.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  63. Lu YS, Lien HC, Yeh PY, Kuo SH, Chang WC, Kuo ML, Cheng AL. Glucocorticoid receptor expression in advanced non-small cell lung cancer: clinicopathological correlation and in vitro effect of glucocorticoid on cell growth and chemosensitivity. Lung Cancer. 2006 Sep; 53(3):303-10. PMID: 16806572.
    Citations: 11     Fields:    Translation:Humans
  64. Ch'ang HJ, Wang CC, Cheng AL, Hsu C, Lu YS, Chang MC, Lin JT, Wang HP, Shiah HS, Liu TW, Chang JY, Whang-Peng J, Chen LT. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer. J Gastroenterol Hepatol. 2006 May; 21(5):874-9. PMID: 16704539.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  65. Lu YS, Yeh PY, Chuang SE, Gao M, Kuo ML, Cheng AL. Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-{kappa}B activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa. J Endocrinol. 2006 Feb; 188(2):311-9. PMID: 16461557.
    Citations: 3     Fields:    Translation:HumansCells
  66. Lu YS, Lien HC, Yeh PY, Yeh KH, Kuo ML, Kuo SH, Cheng AL. Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors. World J Gastroenterol. 2005 Oct 28; 11(40):6373-80. PMID: 16419168.
    Citations: 5     Fields:    Translation:HumansCells
  67. Su WP, Wen CC, Hsiung CA, Su IJ, Cheng AL, Chang MC, Tsao CJ, Kao WY, Uen WC, Hsu C, Hsu CH, Lu YS, Tien HF, Chao TY, Chen LT, Whang-Peng J, Chen PJ. Long-term hepatic consequences of chemotherapy-related HBV reactivation in lymphoma patients. World J Gastroenterol. 2005 Sep 14; 11(34):5283-8. PMID: 16149133.
    Citations: 3     Fields:    Translation:Humans
  68. Yeh KH, Lu YS, Hsu CH, Lin JF, Hsu C, Kuo SH, Li SJ, Cheng AL. Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer. Oncology. 2005; 69(1):88-95. PMID: 16088236.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  69. Lu YS, Kuo SH, Huang CS. Recent advances in the management of primary breast cancers. J Formos Med Assoc. 2004 Aug; 103(8):579-98. PMID: 15340657.
    Citations: 6     Fields:    Translation:Humans
  70. Lu YS, Hsu C, Li CC, Kuo SH, Yeh KH, Yang CH, Hsu CH, Wu CY, Cheng AL. Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma. Hepatogastroenterology. 2004 May-Jun; 51(57):815-9. PMID: 15143923.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  71. Yeh KH, Lu YS, Hsiao CH, Cheng AL. High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma. Anticancer Res. 2003 Nov-Dec; 23(6D):5133-7. PMID: 14986591.
    Citations: 1     Fields:    Translation:Humans
  72. Hsu C, Huang CS, Chao TY, Lu YS, Bu CF, Chen MM, Chang KJ, Cheng AL. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma. Cancer. 2002 Nov 15; 95(10):2044-50. PMID: 12412156.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  73. Hsu CH, Cheng AL, Hsu C, Yang CH, Lu YS, Lin CC, Bu CF, Yeh KH. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil. Anticancer Res. 2002 Nov-Dec; 22(6B):3621-7. PMID: 12552966.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  74. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M, Cheng AL. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol. 2002 May 01; 63(9):1709-16. PMID: 12007574.
    Citations: 33     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lu's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (392)
Explore
_
Co-Authors (1)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.